Calibrated for success — Defeating solid tumors with living medicines

Bio4t2 develops chimeric antigen receptor T cell (CAR-T) therapies to treat patients with solid tumors

Bio4t2 develops CAR-T cell

CAR-T for Solid Tumors

Bio4t2 uses its exclusive PrismCoreTM platform to genetically modify T cells to express chimeric antigen receptors (CARs) tuned in the laboratory to recognize self-antigens when overexpressed on solid tumors. Using algorithmic learning coupled with biological observations, Bio4t2's technology generates CAR-T with effector functions that are activated as a function of antigen density. The calibrated CAR-T specifically attacks cancer cells that commonly overexpress self-antigen and spares vital normal structures that express reduced levels of the self-antigen.

Bio4t2's proprietary Bio-EngineTM further advances the treatment of invasive cancer therapies. This technology enhances persistence of CAR-T after infusion and avoids the need for preparative (lymphodepleting) chemotherapy before infusion. Both of these attributes are achieved by creating CAR-T that are engineered to be boosted in numbers upon interacting for circulating blood cells.

Both PrismCore and Bio-Engine have been used to produce Bio4t2’s lead product that is undergoing clinical testing. The CAR-T termed B4t2-001 recognizes the tumor target BT-001 that is overexpressed on lung, colorectal, gastric, pancreatic and breast cancers.

PrismCore and Bio-Engine are also being used to generate Bi-CAR-T. An advantage of Bi-CAR-T is the ability to simultaneously target two antigens. This extends the range of solid tumors that can be recognized and reduces the chance of antigen-negative tumor relapse and therefore increases the numbers of patients that may benefit from Bi-CAR-T.

Learn more about Bio4t2

View Company Introduction Video
Bio4t2 Featured Image

PrismCore Platform produces CAR-T against solid tumors

See the science behind Bio4t2
Bio4t2 LinkedIn
Bio4t2TM, PrismCoreTM and Bio-EngineTM are trademarks of Bio4t2. Privacy Page »